Webinar Now Available: Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity

Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar, Katie McKenna, PhD, will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.

Topics covered:

  • Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
  • Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
  • Assessing T cell functionality with single-cell proteomics

Watch the on-demand webinar below:

Share This Article
Follow the Data.
Your Data is Secure

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.